This Page Is Inserted by IFW Operations and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.



United States Patent and Trademark Office

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEHARK OFFICE
WASHINGTON, DC 2023

APPLICATION NO./
CONTROL NO.

FILING DATE

FIRST NAMED INVENTOR /
PATENT IN REEXAMINATION

ATTORNEY DOCKET NO.



EXAMINER

ART UNIT

1203

PAPER

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents


This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

APPLICANT IS GIVEN 30 days FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R.. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a perition accompanied by the extension fee under the provisions of 3.7 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Anne R. Kubelik whose telephone number is (703) 308-5059, which sometime in January will change to (571) 272-0801. The examiner can normally be reached on Monday through Friday, 8:30 am - 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Amy Nelson, can be reached at (703) 308-4310. The fax number for the organization where this application or proceeding is assigned is (703) 306-3218.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Vintinia 22313-1450

APPLICATION NO. FIRST NAMED INVENTOR FILING DATE ATTORNEY DOCKET NO. CONFIRMATION NO. 10/019,823 06/12/2002 Jonathan Griffin 5YN-128 9917 7590 12/17/2003 EXAMINER Colleen Superko KUBELIK, ANNE R Hale & Dorr PAPER NUMBER 60 State Street ART UNIT Boston, MA: 02109 1638 DATE MAILED: 12/17/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

com to Sel

HALE & DORR DOCKETING

RE: 09846.298 US/

Action Date: 1500516 TEd

Action to be Taken: None.

Ducksted By MB On: 0-2200

2004 0			
	Application No.	Applicant(s)	
Notice to Complete the Company of	10/019,823	GRIFFIN ET AL.	
Notice to Comply	Examiner	Art Unit	
	Anne R. Kubelik	1638	

HALE & DORR LLP

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e):
- 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☑ 7. Other: CRF DOES NOT MATCH APPLICATION SPECIFICATION

Applicant Must Provide:

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

Patentin Software Program Support

Technical Assistance......703-287-0200

To Purchase Patentin Software......703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY



Syngenta
Patent and Trademark Dept.
3054 Cornwallis Road
Research Triangle Park,
North Carolina 27709-2257
Tel (919) 597-3031
Fax (919) 541-8689

22-Dec-03

ATTN: Michae	l Lee	Our Ref:	50431/PPDUSPCT	
Syngenta Lim				
	ll International Researc	:h		
Centre				
Bracknell	DCAO CVZ			
GB-Berkshire	RG42 61A			
DUE DATE:	RESPO	ONSE DATE:		
January 17,		MOL DAIL.		
Re:	Application of GRIFFIN I	ET AL.		
	Case No. 50431/PPDUSPCT			
	Application No. 10/0198	23		
Ladies and Ge	entlemen:			
Enclosed are	copies of the following	•		
Filing Phase		•		
	Application filed as a Pu	riority Appliant	ri on	
Regular Application filed as a Priority Application Provisional Application filed as a Priority Application				
<u> </u>				
Petition to Convert Regular Application into a Provisional Application Regular Application Based On Provisional Application(s) and/or Foreign				
		rsional Applica	ition(s) and/or Foreign	
Applicati				
CPA Transmittal Form				
Continuation of Application No Division of Application No				
Division				
Continuation-in-part of Application No.				
Entry of PCT Application Into National Stage				
Official Filing Receipt (Dated:)				
Other Document(s)				
rosecution P	hase			
Paper(s)	received from the PTO -	Notice To Compl	y (Due Date: January 17,	
2004) —				
_ Paper(s)	sent to the PTO			
Other Doc	ument(s)			
ssuance	Dilawana (D-4-4)	,		
	Allowance (Dated:	_ '		
Issue Notification Form Patent (three soft copies)				
iscellaneous	• • • • • • • • • • • • • • • • • • •			
	Abandonment (Dated:)		
] Notice of	Recordation of Assignmen	nt Document (Re	cordation Date:	
] Other Doc		, , , , , , , , , , , , , , , , , , , ,		
			•	

Very truly yours,

Oksana Buynitzky